Smith & Nephew plc (LON:SN) has been assigned a consensus rating of “Hold” from the sixteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is GBX 1,208.67 ($17.99).
In other Smith & Nephew plc news, insider Freestone,Robin purchased 15,000 shares of the company’s stock in a transaction dated Friday, October 30th. The stock was bought at an average cost of GBX 1,101 ($16.38) per share, for a total transaction of £165,150 ($245,758.93).
A number of analysts have recently commented on SN shares. Deutsche Bank reissued a “buy” rating and issued a GBX 1,250 ($18.60) price objective on shares of Smith & Nephew plc in a research note on Monday, October 12th. Barclays reaffirmed an “overweight” rating and set a GBX 1,260 ($18.75) target price on shares of Smith & Nephew plc in a research report on Monday, October 12th. Goldman Sachs reaffirmed a “buy” rating on shares of Smith & Nephew plc in a research report on Wednesday, November 11th. Morgan Stanley reaffirmed an “underweight” rating and set a GBX 1,074 ($15.98) target price on shares of Smith & Nephew plc in a research report on Wednesday, November 11th. Finally, Credit Suisse reaffirmed a “neutral” rating and set a GBX 1,105 ($16.44) target price on shares of Smith & Nephew plc in a research report on Wednesday, November 11th.
Smith & Nephew plc (LON:SN) traded down 2.8974% during mid-day trading on Monday, hitting GBX 1173.0000. The company had a trading volume of 1,039,703 shares. Smith & Nephew plc has a one year low of GBX 1,006.20 and a one year high of GBX 1,217.00. The company’s market cap is GBX 10.49 billion. The company’s 50 day moving average price is GBX 1,121.63 and its 200-day moving average price is GBX 1,132.79.
Smith & Nephew plc is a global medical devices business operating in the markets for advanced surgical devices, which includes orthopedic reconstruction, trauma and sports medicine and advanced wound management. The Company operates in two segments: Advanced Surgical Devices and Advanced Wound Management. The Company’s Advanced Surgical Devices (LON:SN) segment offers products and technologies, which include orthopedic reconstruction, trauma and extremities, sports medicine joint repair, arthroscopy enabling technologies and other advanced surgical devices (ASD). The Company’s Advanced Wound Management (AWM) segment offers products, including Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives. The Company operates across the world and has distribution channels in over 100 countries.